Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA

May 13, 2025

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.

Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics

May 13, 2025

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

May 11, 2025

Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs

May 10, 2025

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 09, 2025

Featured Content

Watch the full IGBA's Global Biosimilars Week LIVE Webinar!

Watch the Global Biosimilars Week LIVE Webinar!

How Streamlining Development Can Save the US Biosimilar Industry

AAM White Paper Breaks Down Drug Shortage Crisis: Causes and Solutions

several filled syringes in different sizes and colors

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

The Top 5 Biosimilar Articles for the Week of May 5

May 9th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 5, 2025.

Targeted Reimbursement Encourages Oncology Biosimilar Use

May 7th 2025

By Skylar Jeremias

Article

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 6th 2025

By Cameron Santoro

Article

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

BioRationality: A New Bill to Transform the Future of Biosimilars

May 5th 2025

By Sarfaraz K. Niazi, PhD

Article

Escaping the Void: All Things Biosimilars With Craig & G

May 4th 2025

By Craig Burton

Podcast

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."

Future Directions for Ustekinumab Biosimilars in Crohn Disease

May 3rd 2025

By Deana Ferreri, PhD

Article

The Top 5 Biosimilar Articles for the Week of April 28

May 2nd 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 28, 2025.

Samsung Bioepis Report Signals Turning Point for US Biosimilars

May 1st 2025

By Skylar Jeremias

Article

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.

Biosimilars Policy Roundup: April 2025

April 30th 2025

By Skylar Jeremias

Article

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar access at Festival of Biologics USA to close out April 2025.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

By Skylar Jeremias

Article

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.